1. Computational Modeling of an Epidermal Growth Factor Receptor Single-Mutation Resistance to Cetuximab in Colorectal Cancer Treatment
- Author
-
Noelia Ferruz, Gianni De Fabritiis, and Ignasi Buch
- Subjects
medicine.medical_specialty ,Colorectal cancer ,Neuregulin-1 ,General Chemical Engineering ,Cetuximab ,Antineoplastic Agents ,Drug resistance ,Molecular Dynamics Simulation ,Library and Information Sciences ,Antibodies, Monoclonal, Humanized ,Ligands ,medicine.disease_cause ,Internal medicine ,medicine ,Humans ,Epidermal growth factor receptor ,Mutation ,Epidermal Growth Factor ,biology ,Chemistry ,Wild type ,General Chemistry ,Single-Domain Antibodies ,Transforming Growth Factor alpha ,medicine.disease ,Computer Science Applications ,ErbB Receptors ,Endocrinology ,Drug Resistance, Neoplasm ,Monoclonal ,Cancer research ,biology.protein ,Thermodynamics ,Antibody ,Colorectal Neoplasms ,medicine.drug - Abstract
Extracellular S468R mutation of the epidermal growth factor receptor (EGFR) was recently identified as the cause of resistance to cetuximab, a widely used drug in colorectal cancer treatment. Here, we have determined the binding free energies of cetuximab's Fab V(H)-V(L) domains and endogenous EGF ligand to wild type and S468R EGFR by high-throughput molecular dynamics. This work provides a possible mechanism of resistance in terms of increased competition, an hypothesis that can be further validated experimentally.
- Published
- 2013
- Full Text
- View/download PDF